Dudediligence.

Nektar Therapeutics

NKTRNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$24.1MSep ’24$29.2MDec ’24$10.5MMar ’25$11.2MJun ’25$11.8MSep ’25$21.8MDec ’25$10.9MMar ’26$10.1MJun ’26
Net income, by quarter
−$37.1MSep ’24$7.3MDec ’24−$50.9MMar ’25−$41.6MJun ’25−$35.5MSep ’25−$36.0MDec ’25−$44.9MMar ’26−$40.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$101.9M$92.1M$90.1M$98.4M$55.2M
Gross profit$77.0M$70.4M$56.4M$67.7M$55.2M
Operating income−$446.1M−$376.2M−$263.7M−$105.2M−$140.1M
Net income−$523.8M−$368.2M−$276.1M−$119.0M−$164.0M
Operating cash flow−$412.7M−$304.0M−$192.6M−$175.7M−$208.5M
Free cash flow−$427.6M−$309.7M−$193.5M−$177.2M−$208.7M
Cash$25.2M$88.2M$35.3M$44.3M$15.1M
Shares outstanding185.5M188.6M191.4M12.4M20.4M